Combined nucleotide metabolism pathways

Combined nucleotide metabolism pathways encompass the complex biochemical processes of purine and pyrimidine biosynthesis, salvage, and degradation (NCBI, StatPearls: Nucleotide Metabolism). These pathways are essential for providing the building blocks required for DNA replication and RNA transcription, as well as maintaining energy currency (ATP/GTP) and signaling molecules (cAMP/cGMP) within the cell (Wikipedia: Nucleotide metabolism). Because rapidly proliferating cells, such as cancer cells and activated lymphocytes, have a high demand for nucleotides, these pathways are major targets for chemotherapy and immunosuppressive therapy (PubMed: PMID 28673544). Drugs interacting with these pathways, known as antimetabolites, often mimic natural nucleotides to inhibit key enzymes like dihydrofolate reductase or thymidylate synthase (PubChem: Methotrexate). Dysregulation of these pathways is linked to various pathologies, including gout, Lesch-Nyhan syndrome, and severe combined immunodeficiency (SCID) (NIH: Genetics Home Reference). Therapeutic intervention often involves the use of structural analogs that compete with natural substrates, effectively halting cell cycle progression in the S-phase. Monitoring of these pathways is clinically significant, as genetic polymorphisms in enzymes like TPMT can lead to severe drug toxicities.

Other names

Purine and pyrimidine metabolismNucleotide biosynthesis and degradationNucleotide metabolism

Inhibition of enzymes involved in purine and pyrimidine de novo synthesis and salvage pathways, leading to the depletion of nucleotide pools and inhibition of nucleic acid synthesis.